Business Wire

GEMALTO

14.5.2018 07:02:08 CEST | Business Wire | Press release

Share
Gemalto Strengthens Trust in Smart Energy with Its New End-to-End Security Solution

Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, is strengthening trust in the smart energy sector with an end-to-end security solution which protects the entire ecosystem. Deployed by smart meter makers and distribution systems operators, the offer provides seamless connectivity solutions, secure digital identities and security lifecycle management for the long life of smart meters, as threats and stakeholders evolve over time. The solution protects connected energy assets and the data they exchange, allowing people and businesses to trust the expanding smart grid.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180513005007/en/

Secure smart grids improve sustainability, efficiency and reduce threats
Today’s highly successful smart grids have become comprehensive IoT networks with millions of connected meters that share massive real time data about people, businesses and energy consumption. The valuable insight they provide enables consumers to save on energy bills and utilities and energy players to better balance supply and demand. It is also crucial information to help integrate renewable energy sources, helping to improve sustainability. As the marketplace and number of connections continues to expand by an estimated 30% each year1 , so does the cyberattack surface. The motivations for hacking this critical infrastructure are high and diverse: energy consumption fraud, insight into households’ activity and absence, grid instability, pressure on governments, ID theft. Digital security is paramount to an efficient grid´s success.

Click to watch the IoT Smart Energy video

Gemalto protects and secures the expanding smart grid sector
The dedicated Gemalto cybersecurity solution for electric utilities establishes a foundation of trust at the very core of the ecosystem by establishing end-to-end security between energy meters, data concentrators and energy companies’ back-end systems. Rugged and reliable IoT connectivity modules ensure 24/7 data availability. A strong and unique digital identity system is implemented at the manufacturing stage to ensure devices and applications can strongly authenticate themselves, proving their legitimacy to access sensitive data. Leading-edge encryption technology safeguards against data tampering and strong security lifecycle management enables remote security and data access updates, without costly truck rolls.

“The smart energy ecosystem is one of the most advanced in terms of security requirements because of the potentially disastrous consequences of malicious hacking,” said Guillaume Lafaix, senior vice president Mobile Services and IoT, Gemalto. “The Gemalto cybersecurity solution for Utilities ensures the integrity and confidentiality of smart meter data while defending against hacking and emerging threats that are typical to this business.”

To learn more about the Gemalto cyber-security solution for Utilities, please visit us at African Utility Week from May 15-17 in Cape Town. Or check our dedicated webpages:
Gemalto at African Utility Week
Gemalto smart metering solutions
Gemalto security lifecycle management for Utilities

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com , or follow @gemalto on Twitter.

1 https://www.technocracy.news/index.php/2017/08/03/global-smart-grid-market-growing-at-30-per-year/

Contact:

Gemalto media:
Tauri Cox, +1 512 257 3916
North America
tauri.cox@gemalto.com
or
Sophie Dombres, +33 4 42 36 57 38
Europe Middle East & Africa
sophie.dombres@gemalto.com
or
Jaslin Huang, +65 6317 3005
Asia Pacific
jaslin.huang@gemalto.com
or
Enriqueta Sedano, +52 5521221422
Latin America
enriqueta.sedano@gemalto.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye